• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oyster Point Pharma, Inc. - common stock (NQ:OYST)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oyster Point Pharma, Inc. - common stock

News headline image
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
December 07, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From Oyster Point Pharma, Inc.
Via GlobeNewswire
News headline image
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From Oyster Point Pharma, Inc.
Via GlobeNewswire
News headline image
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
November 08, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
November 08, 2022
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
November 07, 2022
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development 
Via Spotlight Growth
News headline image
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
November 07, 2022
From Halper Sadeh LLC
Via Business Wire
News headline image
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
November 07, 2022
From Oyster Point Pharma, Inc.
Via GlobeNewswire
News headline image
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
November 02, 2022
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET 
From Oyster Point Pharma, Inc.
Via GlobeNewswire
News headline image
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From Oyster Point Pharma, Inc.
Via GlobeNewswire
News headline image
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From Oyster Point Pharma, Inc.
Via GlobeNewswire
News headline image
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
July 27, 2022
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap